Leading platform capabilities
Our platform, based on deep microbial culturing know-how, combines our leading gut bacterial reference genome database, which includes previously unidentified bacteria, a linked culture collection and high-performance, proprietary bioinformatics tools. When applied to clinical trial datasets, these tools power Microbiotica’s precision microbiome profiling which underpins our ability to discover and develop novel therapeutic products.
How our LBP clinic-led discovery platform works
The interaction between microbiome and host is complex and only partially understood. Our approach to unlocking the therapeutic potential of the microbiome is to identify which bacteria are associated with beneficial outcomes in specific patient populations, and then to investigate the mechanisms by which they exert their effect.
We analyse the microbiome profiles of patients in clinical trials to identify signatures of bacteria associated with clinical benefit using advanced bioinformatics including machine learning. Bacterial strains associated with positive outcomes and with a good safety and developability profile are selected to form lead LBPs.
Advantages of our precision microbiome medicines
Clinical validation from the start
Platform enables clinic-led discovery; precisely identifying bacteria associated with beneficial health outcome in specific patient populations.
High-resolution microbiome profiles
Capability to identify bacteria and match to strains in our culture collection allows us to identify novel microbiome signatures.
Enable precision medicine
Our LBPs target the patient groups from which they were discovered.
Robust efficacy from multiple mechanisms
Increasing our understanding of mechanisms of action by which the LBPs interact with the host and exert treatment effect. In most cases, multiple mechanisms are at play.
Choice of therapeutic strategies
There are opportunities to develop as standalone therapies or co-therapies to enhance the efficacy of other drug modalities.
Excellent safety enabling direct to patient clinical trials
Our bacteria are natural, commensal strains with an assumed human safety and tolerability profile, allowing progression directly into patient clinical trials.
Our first clinical trials will measure the safety, engraftment and initial signs of efficacy of our products in immuno-oncology and ulcerative colitis, areas with high levels of unmet need.
Advantages of our precision microbiome medicines
-
Clinical validation from the start
Our platform enables clinic-led discovery; precisely identifying bacteria associated with beneficial health outcome in specific patient populations.
-
High-resolution microbiome profiles
Our capability to identify bacteria and match to strains in our culture collection allows us to identify novel microbiome signatures.
-
Enable precision medicine
Our LBPs target the patient groups from which they were discovered.
-
Robust efficacy from multiple mechanisms
We are increasing our understanding of mechanisms of action by which the LBPs interact with the host and exert treatment effect. In most cases, multiple mechanisms are at play.
-
Choice of therapeutic strategies
There are opportunities to develop as standalone therapies or co-therapies to enhance the efficacy of other drug modalities.
-
Excellent tolerability and safety
Our bacteria are natural, commensal strains. We therefore anticipate good tolerability and safety.
-
Direct to patient clinical trials
The assumed safety profile of human, commensal bacteria allows progression directly into patient clinical trials. Our first clinical trials will measure the safety, engraftment and initial signs of efficacy of our products in immuno-oncology and ulcerative colitis, areas with high levels of unmet need.
Multiple therapeutic opportunities
At Microbiotica, we harness the power of our cutting-edge technology to pinpoint the exact bacterial strains linked to positive health outcomes in targeted patient groups. This breakthrough approach serves as the foundation for our innovation product development programmes. Through rigorous screening processes and advanced methodologies we carefully select and assemble the optimal bacterial consortia for our LBPs.
A suite of in vitro human cell assays and disease models is leveraged to validate our lead candidates and elucidate the mechanisms by which an LBP interacts with the biology.
Multiple therapeutic opportunities
At Microbiotica, we harness the power of our cutting-edge technology to pinpoint the exact bacterial strains linked to positive health outcomes in targeted patient groups. This breakthrough approach serves as the foundation for our innovation product development programmes. Through rigorous screening processes and advanced methodologies we carefully select and assemble the optimal bacterial consortia for our LBPs.
A suite of in vitro human cell assays and disease models is leveraged to validate our lead candidates and elucidate the mechanisms by which an LBP interacts with the biology.
Preclinical studies to validate lead LBP candidate and elucidate Mechanism of Action
A suite of in vitro human cell assays and disease models is leveraged to validate our lead candidates and elucidate the mechanisms by which an LBP interacts with the biology.
